Cost of managing complications resulting from type 2 diabetes mellitus in Canada
about
The impact of diabetes mellitus and other chronic medical conditions on health-related Quality of Life: is the whole greater than the sum of its parts?Losing a foot versus losing a dollar; a systematic review of cost studies in diabetic foot complications.Economic Value of Improved Accuracy for Self-Monitoring of Blood Glucose Devices for Type 1 Diabetes in Canada.Self-measurement of blood glucose in patients with type 2 diabetes: a health economic assessmentCost-effectiveness of insulin analogues for diabetes mellitus.Effectiveness of the smart care service for diabetes managementPharmacoeconomic evaluation of diabetic nephropathic patients attending nephrology department in a tertiary care hospital.Screening for diabetic retinopathy and nephropathy in patients with diabetes: a nationwide survey in Korea.Economic burden of illness associated with diabetic foot ulcers in Canada.Medical costs associated with type 2 diabetes complications and comorbidities.Economic evaluation of hormonal therapies for postmenopausal women with estrogen receptor-positive early breast cancer in CanadaCosts of diabetes mellitus in KoreaThe prevalence of macrovascular complications among diabetic patients in the United Arab EmiratesHealth care costs in people with diabetes and their association with glycemic control and kidney function.Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United KingdomEvaluating the true cost of hypertension management: evidence from actual practice.Abnormal calcium homeostasis in peripheral neuropathies.Costs and Quality of Life in Diabetic Macular Edema: Canadian Burden of Diabetic Macular Edema Observational Study (C-REALITY).Description of a New Predictive Modeling Approach That Correlates the Risk and Associated Cost of Well-Defined Diabetes-Related Complications With Changes in Glycated Hemoglobin (HbA1c).Cost analysis for efficient management: diabetes treatment at a public district hospital in Thailand.Economic analysis of insulin initiation by pharmacists in a Canadian setting: The RxING study.Projecting prevalence, costs and evaluating simulated interventions for diabetic end stage renal disease in a Canadian population of aboriginal and non-aboriginal people: an agent based approach.Consumption, perceptions and knowledge of soy among adults with type 2 diabetes.Soya protein does not affect glycaemic control in adults with type 2 diabetes.Cost-effectiveness of G5 Mobile continuous glucose monitoring device compared to self-monitoring of blood glucose alone for people with type 1 diabetes from the Canadian societal perspective.Cost-effectiveness of magnetic resonance carotid plaque imaging for primary stroke prevention in Canada.Relationship Between Adiponectin and apoB in Individuals With Diabetes in the Atlantic PATH Cohort.Healthcare costs and utilization of diabetes-related complications in Taiwan: A claims database analysisCognitive Behavioural Therapy for Psychosis: A Health Technology Assessment
P2860
Q24799452-C1D365F0-E7F8-4843-AD68-233FCD48673AQ30235338-1BEE26EB-A61A-4020-839A-F05B95D8E765Q30278856-9E970DFA-6E8A-4E09-BD92-07AFFA6DD16CQ30382232-FDFB7350-5FB5-4833-BBAF-E61BF36AA2DDQ30485897-FA1A96EB-6434-4867-9700-DB0D6EEABBFCQ33442067-382D9307-D617-4E68-B8D5-305759ECCB12Q33573338-0CB4EC9E-B64D-4AA4-ABAE-499B63B9F27BQ34717944-B6DC6EE9-D669-4D93-94D9-0D34454DA251Q35018610-CA9EB2CC-EC0C-4DC2-AF6E-CA164748E295Q35110549-CF8F2C74-AB43-4118-BE60-36C9F8B666D8Q35445037-33E60221-59E3-41B0-84AA-45A4FA6785AFQ35661417-D0317A92-68AB-4DC8-A320-B2BB395E1D27Q36168162-AF6A9952-0D10-4C5B-BE64-57054B7DD280Q36782623-D5FC9406-30B2-4473-A0B6-D84587ACF91DQ36897192-8568327B-9473-47CB-A359-001CFFA67A11Q37609345-F37C80D1-DFCF-4AC3-B771-FAFF4D618657Q37662579-B4AE0A4D-FCDF-4ADF-8494-43CDE2C58D06Q37699938-EA9C1CB9-D6F0-4CCC-A347-F043674B065EQ38924071-1DCFD58E-9790-4F52-AEDF-31420339DD72Q39709882-B9B3BFC1-294A-4E12-98E3-BB922F01976EQ39744751-3CBE57A0-6FC2-48D3-83D8-0FDE6E066C08Q40058808-B78DC66E-28DF-42CA-A7E4-DA2B9D20132FQ43261389-3B4FD709-17A6-430B-909B-88CA359DA95CQ43286317-8A416D2B-F855-4EE1-AFD0-15676639AD48Q47878608-FC213172-D295-4F5E-AC26-6B1D9E80983BQ48115342-885CF5B1-7C2C-43C6-B741-B5D6E3BA4C44Q52398814-03AA1510-918B-4359-BD5A-3CF9D7C2BE52Q58802089-B05C64A1-C829-40CB-A715-1590D763A6D8Q59137630-E6ACC3A5-4FFE-4A6D-923D-649959EA1A93
P2860
Cost of managing complications resulting from type 2 diabetes mellitus in Canada
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Cost of managing complications resulting from type 2 diabetes mellitus in Canada
@ast
Cost of managing complications resulting from type 2 diabetes mellitus in Canada
@en
Cost of managing complications resulting from type 2 diabetes mellitus in Canada
@nl
type
label
Cost of managing complications resulting from type 2 diabetes mellitus in Canada
@ast
Cost of managing complications resulting from type 2 diabetes mellitus in Canada
@en
Cost of managing complications resulting from type 2 diabetes mellitus in Canada
@nl
prefLabel
Cost of managing complications resulting from type 2 diabetes mellitus in Canada
@ast
Cost of managing complications resulting from type 2 diabetes mellitus in Canada
@en
Cost of managing complications resulting from type 2 diabetes mellitus in Canada
@nl
P2860
P356
P1476
Cost of managing complications resulting from type 2 diabetes mellitus in Canada
@en
P2093
Amanda R Patrick
Judith A O'Brien
P2860
P2888
P356
10.1186/1472-6963-3-7
P407
P50
P577
2003-03-21T00:00:00Z
P5875
P6179
1032136158